Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain themaximumbenefit from FCR. In this observationalmulticenter retrospective analysis of 404 CLL patients receiving frontline FCR, the combination of three biomarkers that arewidely tested before treatment (IGHV mutation status, 11q deletion and 17p deletion; available in 80% of the study cohort) allowed to identify a very low-risk category of patients carrying mutated IGHV genes but neither 11q or 17p deletion that accounted for 28%of all cases. The majority of very low-risk patients (71%) remainedfreeofprogression after treatmentandtheir hazard of relapsedecreased after 4 years fromFCR.Thelife expectancy of very low-risk patients (91% at 5 years) was superimposable to that observed in the matched normal general population, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group. These findings need a prospective validation and may be helpful for the design of clinical trials aimed at comparing FCR to new targeted treatments of CLL, and, possibly, for optimized disease management. © 2015 by The American Society of Hematology.

Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia

ZAJA, Francesco;
2015-01-01

Abstract

Fludarabine, cyclophosphamide, and rituximab (FCR) has represented a significant treatment advancement in chronic lymphocytic leukemia (CLL). In the new scenario of targeted agents, there is an increasing interest in identifying patients who gain themaximumbenefit from FCR. In this observationalmulticenter retrospective analysis of 404 CLL patients receiving frontline FCR, the combination of three biomarkers that arewidely tested before treatment (IGHV mutation status, 11q deletion and 17p deletion; available in 80% of the study cohort) allowed to identify a very low-risk category of patients carrying mutated IGHV genes but neither 11q or 17p deletion that accounted for 28%of all cases. The majority of very low-risk patients (71%) remainedfreeofprogression after treatmentandtheir hazard of relapsedecreased after 4 years fromFCR.Thelife expectancy of very low-risk patients (91% at 5 years) was superimposable to that observed in the matched normal general population, indicating that neither the disease nor complications of its treatment affected survival in this favorable CLL group. These findings need a prospective validation and may be helpful for the design of clinical trials aimed at comparing FCR to new targeted treatments of CLL, and, possibly, for optimized disease management. © 2015 by The American Society of Hematology.
2015
Pubblicato
https://ashpublications.org/blood/article-lookup/doi/10.1182/blood-2015-05-647925
File in questo prodotto:
File Dimensione Formato  
Rossi_molecular_Blood_2015.pdf

Accesso chiuso

Tipologia: Documento in Versione Editoriale
Licenza: Copyright Editore
Dimensione 743.99 kB
Formato Adobe PDF
743.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
blood-2015-05-647925-1.pdf

Accesso chiuso

Descrizione: Supplementary Appendix
Tipologia: Altro materiale allegato
Licenza: Digital Rights Management non definito
Dimensione 917.25 kB
Formato Adobe PDF
917.25 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/2955617
Citazioni
  • ???jsp.display-item.citation.pmc??? 69
  • Scopus 185
  • ???jsp.display-item.citation.isi??? 182
social impact